Patents by Inventor Gozoh Tsujimoto
Gozoh Tsujimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9873916Abstract: This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.Type: GrantFiled: April 25, 2012Date of Patent: January 23, 2018Assignees: TORAY INDUSTRIES, INC., KYOTO UNIVERSITYInventors: Akira Myomoto, Satoko Kozono, Fumiaki Sato, Masakazu Toi, Takayuki Ueno, Zhipeng Wang, Gozoh Tsujimoto, Kazuharu Shimizu
-
Publication number: 20160326251Abstract: Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic agent for cancer comprises as an effective component an antibody that undergoes antigen-antibody reaction with FGFRL1 to suppress the growth of cancer cells, or an antigen-binding fragment thereof. The method for predicting the prognosis of cancer comprises investigating the expression level of FGFRL1 in a cancer tissue separated from a living body, and, in this method, a high expression level of FGFRL1 indicates poor prognosis.Type: ApplicationFiled: July 28, 2016Publication date: November 10, 2016Applicant: KYOTO UNIVERSITYInventors: Soken TSUCHIYA, Gozoh TSUJIMOTO, Kazuharu SHIMIZU, Yutaka SHIMADA, Kazuhiro TSUKADA
-
Patent number: 8949157Abstract: A data processing method for an estimation of compound-protein interaction using both chemical substance information, such as a chemical property of the compound, and biological information, such as sequence information of genes to rationally and efficiently screen compounds. First space representing space coordinates of a first chemical substance group and second space representing space coordinates of a second chemical substance group are defined, and the first chemical substance group is characterized by a first characteristic amount and the second chemical substance group is characterized by a second characteristic amount, and map transformation of the coordinates of the first space and the coordinates of the second space results in the solution so as to increase the correlation between the first space and the second space using a multivariable analysis technique or a machine learning method.Type: GrantFiled: November 20, 2008Date of Patent: February 3, 2015Assignee: Kyoto UniversityInventors: Yasushi Okuno, Kei Taneishi, Gozoh Tsujimoto
-
Patent number: 8945849Abstract: This invention relates to a composition, kit, or DNA chip for use in diagnosis of esophageal cancer, which comprises a plurality of polynucleotides selected from the group consisting of polynucleotides whose expression levels are varied in esophageal cancer tissues obtained from esophageal cancer patients when compared with cancer-free esophageal tissues obtained from esophageal cancer patients, mutants thereof, and fragments thereof, and to a method for detecting esophageal cancer using the composition, kit, or DNA chip.Type: GrantFiled: May 21, 2009Date of Patent: February 3, 2015Assignees: Toray Industries, Inc., Kyoto UniversityInventors: Akira Myomoto, Satoko Kozono, Hideo Akiyama, Hitoshi Nobumasa, Yutaka Shimada, Gozoh Tsujimoto
-
Publication number: 20140335090Abstract: Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic agent for cancer comprises as an effective component an antibody that undergoes antigen-antibody reaction with FGFRL1 to suppress the growth of cancer cells, or an antigen-binding fragment thereof. The method for predicting the prognosis of cancer comprises investigating the expression level of FGFRL1 in a cancer tissue separated from a living body, and, in this method, a high expression level of FGFRL1 indicates poor prognosis.Type: ApplicationFiled: March 30, 2012Publication date: November 13, 2014Applicant: KYOTO UNIVERSITYInventors: Soken Tsuchiya, Gozoh Tsujimoto, Kazuharu Shimizu, Yutaka Shimada, Kazuhiro Tsukada
-
Publication number: 20140073533Abstract: This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.Type: ApplicationFiled: April 25, 2012Publication date: March 13, 2014Applicants: KYOTO UNIVERSITY, TORAY INDUSTRIES, INCInventors: Akira Myomoto, Satoko Kozono, Fumiaki Sato, Masakazu Toi, Takayuki Ueno, Zhipeng Wang, Gozoh Tsujimoto, Kazuharu Shimizu
-
Patent number: 8318781Abstract: Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I).Type: GrantFiled: April 25, 2008Date of Patent: November 27, 2012Assignees: Japan Science and Technology Agency, Kyoto University, Nagoya City UniversityInventors: Gozoh Tsujimoto, Akira Hirasawa, Naoki Miyata, Takayoshi Suzuki, Yoshiyuki Takahara, Masaji Ishiguro, Mie Hata
-
Patent number: 8198025Abstract: This invention relates to a composition, kit, or DNA chip comprising polynucleotides and antibodies as probes for detecting, determining, or predicting the presence or metastasis of esophageal cancer, and to a method for detecting, determining, or predicting the presence or metastasis of esophageal cancer using the same.Type: GrantFiled: April 6, 2011Date of Patent: June 12, 2012Assignees: Toray Industries, Inc., Kyoto UniversityInventors: Hideo Akiyama, Satoko Kozono, Akira Myomoto, Osamu Nomura, Hitoshi Nobumasa, Yoshinori Tanaka, Shiori Tomoda, Yutaka Shimada, Gozoh Tsujimoto
-
Publication number: 20110287112Abstract: A prostate cancer progression inhibitor comprises 4-(4-cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid, a salt thereof, a solvate thereof, or a prodrug thereof. 4-(4-Cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid is useful as a prostate cancer progression inhibitor because this butyric acid has, for example, a growth inhibiting effect and a hormone responsiveness recovering effect on prostate cancer that has acquired hormone resistance.Type: ApplicationFiled: January 29, 2010Publication date: November 24, 2011Applicants: ONO PHARMACEUTICAL CO., LTD., KYOTO UNIVERSITYInventors: Osamu Ogawa, Gozoh Tsujimoto, Eijiro Nakamura, Tomomi Kamba, Yosuke Shimizu, Naoki Terada, Toshiya Kanaji, Takayuki Maruyama
-
Publication number: 20110201520Abstract: This invention relates to a composition, kit, or DNA chip comprising polynucleotides and antibodies as probes for detecting, determining, or predicting the presence or metastasis of esophageal cancer, and to a method for detecting, determining, or predicting the presence or metastasis of esophageal cancer using the same.Type: ApplicationFiled: April 6, 2011Publication date: August 18, 2011Applicants: TORAY INDUSTRIES, INC., Kyoto UniversityInventors: Hideo Akiyama, Satoko Kozono, Akira Myomoto, Osamu Nomura, Hitoshi Nobumasa, Yoshinori Tanaka, Shiori Tomoda, Yutaka Shimada, Gozoh Tsujimoto
-
Publication number: 20110184031Abstract: Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I).Type: ApplicationFiled: April 25, 2008Publication date: July 28, 2011Inventors: Gozoh Tsujimoto, Akira Hirasawa, Naoki Miyata, Takayoshi Suzuki, Yoshiyuki Takahara, Masaji Ishiguro, Yoshie Hata
-
Publication number: 20110098185Abstract: This invention relates to a composition, kit, or DNA chip for use in diagnosis of esophageal cancer, which comprises a plurality of polynucleotides selected from the group consisting of polynucleotides whose expression levels are varied in esophageal cancer tissues obtained from esophageal cancer patients when compared with cancer-free esophageal tissues obtained from esophageal cancer patients, mutants thereof, and fragments thereof, and to a method for detecting esophageal cancer using the composition, kit, or DNA chip.Type: ApplicationFiled: May 21, 2009Publication date: April 28, 2011Inventors: Akira Myomoto, Satoko Kozono, Hideo Akiyama, Hitoshi Nobumasa, Yutaka Shimada, Gozoh Tsujimoto
-
Patent number: 7932032Abstract: This invention relates to a composition, kit, or DNA chip comprising polynucleotides and antibodies as probes for detecting, determining, or predicting the presence or metastasis of esophageal cancer, and to a method for detecting, determining, or predicting the presence or metastasis of esophageal cancer using the same.Type: GrantFiled: May 2, 2006Date of Patent: April 26, 2011Assignees: Toray Industries, Inc., Kyoto UniversityInventors: Hideo Akiyama, Satoko Kozono, Akira Myomoto, Osamu Nomura, Hitoshi Nobumasa, Yoshinori Tanaka, Shiori Tomoda, Yutaka Shimada, Gozoh Tsujimoto
-
Publication number: 20100099891Abstract: A data processing method for an estimation of compound-protein interaction using both chemical substance information, such as a chemical property of the compound, and biological information, such as sequence information of genes to rationally and efficiently screen compounds. First space representing space coordinates of a first chemical substance group and second space representing space coordinates of a second chemical substance group are defined, and the first chemical substance group is characterized by a first characteristic amount and the second chemical substance group is characterized by a second characteristic amount, and map transformation of the coordinates of the first space and the coordinates of the second space results in the solution so as to increase the correlation between the first space and the second space using a multivariable analysis technique or a machine learning method.Type: ApplicationFiled: November 20, 2008Publication date: April 22, 2010Applicant: Kyoto UniversityInventors: Yasushi OKUNO, Kei TANEISHI, Gozoh TSUJIMOTO
-
Publication number: 20100004275Abstract: A medicament for suppressing development of tolerance to analgesic effect induced by administration of a narcotic analgesic such as morphine, which comprises an antagonist of the vasopressin receptor 1b as an active ingredient.Type: ApplicationFiled: June 8, 2009Publication date: January 7, 2010Applicants: KYOTO UNIVERSITY, FUKUOKA UNIVERSITY, JAPAN HEALTH SCIENCES FOUNDATIONInventors: Gozoh Tsujimoto, Yukio Takano, Kenji Honda, Akito Tanoue
-
Publication number: 20090270267Abstract: This invention relates to a composition, kit, or DNA chip comprising polynucleotides and antibodies as probes for detecting, determining, or predicting the presence or metastasis of esophageal cancer, and to a method for detecting, determining, or predicting the presence or metastasis of esophageal cancer using the same.Type: ApplicationFiled: May 2, 2006Publication date: October 29, 2009Applicants: TORAY INDUSTRIES, INC., Kyoto UniversityInventors: Hideo Akiyama, Satoko Kozono, Akira Myomoto, Osamu Nomura, Hitoshi Nobumasa, Yoshinori Tanaka, Shiori Tomoda, Yutaka Shimada, Gozoh Tsujimoto
-
Publication number: 20080269155Abstract: A novel agent for therapy and/or prevention of kidney diseases as well as a diagnostic method (detection method) of kidney diseases is disclosed. The agent for therapy and/or prevention of kidney diseases comprises as an effective ingredient a substance which inhibits casein kinase 2. The diagnostic method of kidney diseases according to the present invention comprises measuring activity or content of casein kinase 2, or measuring expression amount of casein kinase 2 gene in a sample separated from body.Type: ApplicationFiled: March 17, 2008Publication date: October 30, 2008Applicant: TORAY INDUSTRIES INC.Inventors: Masateru Yamada, Hajimu Kurumatani, Tetsuo Sudo, Gozoh Tsujimoto
-
Publication number: 20080227802Abstract: A medicament for suppressing development of tolerance to analgesic effect induced by administration of a narcotic analgesic such as morphine, which comprises an antagonist of the vasopressin receptor 1b as an active ingredient.Type: ApplicationFiled: December 26, 2005Publication date: September 18, 2008Applicants: KYOTO UNIVERSITY, FUKUOKA UNIVERSITY, JAPAN HEALTH SCIENCES FOUNDATIONInventors: Gozoh Tsujimoto, Yukio Takano, Kenji Honda, Akito Tanoue
-
Patent number: 7148011Abstract: The differential display method was used to search for a gene whose expression level in eosinophils collected from patients with atopic dermatitis differs in the exacerbation stage and in the remission stage. As a result, gene “2090-05” showing a significant increase in expression in eosinophils of patients in the remission stage was isolated. This gene is usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.Type: GrantFiled: September 21, 2001Date of Patent: December 12, 2006Assignees: Japan as represented by General Director of Agency of National Center for Child Health and Development, Eisai Co., Ltd., Genox Research, Inc.Inventors: Yuji Sugita, Ryoichi Hashida, Kaoru Ogawa, Tomoko Fujishima, Takeshi Nagasu, Gozoh Tsujimoto, Eiki Takahashi
-
Publication number: 20040197786Abstract: RING6 and HLA-DMB are described herein as genes whose expression levels in mononuclear cells greatly differ between a steroid responder group and a poor steroid responder group in atopic dermatitis patients. Specifically, the expression levels of the RING6 and HLA-DMB genes were demonstrated to be reduced in steroid-responsive patients. Using the expression level of such genes in biological samples as markers of steroid responsiveness, the present invention provides a method of testing for steroid responsiveness and a method of screening for compounds that may be used to improve steroid responsiveness.Type: ApplicationFiled: May 25, 2004Publication date: October 7, 2004Inventors: Yuji Sugita, Masayuki Heishi, Shinji Kagaya, Shigemichi Gunji, Gozoh Tsujimoto